Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Maria Teresa Petrucci, Antonio Palumbo, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Bin Jiang, María-Victoria Mateos, Kenneth C. Anderson, Dixie Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul G. Richardson
New England Journal of Medicine, 2008
Abstract
This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan 2009
- Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma 2012
- Three cases of bortezomib-resistant multiple myeloma with extramedullary masses. 2010
- Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma 2007
- Effect of Bortezomib on serum cystatin-C in multiple myeloma 2011
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION 1998
- Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma 1997
- Van de Velde 1920
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. 2003
- Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. 1991